Hydal

Quick links to important sections

Hydal

Method of action: Analgesic

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydal

Property Description
Active ingredient Hydromorphone Hydrochloride
Form Tablet, Solution, Injection, Extended-Release Capsule
Pharmacological class Opioid Analgesic, CNS Depressant
Common use Relief of moderate to severe discomfort
Origin Semisynthetic (derived from Morphine)

What is Hydal and How is it Classified?

Hydal is a potent single-component analgesic medication whose active substance is Hydromorphone Hydrochloride. Pharmacologically, it is classified as a mu-opioid receptor agonist, belonging to the class of Opioid Analgesics and functioning as a Central Nervous System (CNS) depressant. This compound is categorized as a Semisynthetic Opioid, meaning it is chemically manufactured by altering the structure of the naturally occurring opium alkaloid, Morphine, resulting in the derivative Dihydromorphinone. In clinical practice, hydromorphone serves as a therapeutic alternative in cases where common opioids may not provide sufficient relief. Hydromorphone is recognized as a narcotic analgesic.

In What Forms is Hydromorphone Available?

The active ingredient, Hydromorphone Hydrochloride, is prepared in multiple dosage forms to facilitate diverse routes of administration. These preparations include immediate-release oral tablets, liquid oral solutions, and sterile solutions for injection (parenteral administration) for rapid effect. For sustained relief, the medication is also produced in a specialized extended-release capsule form. These preparations consist of the active ingredient combined with either an aqueous vehicle for liquid forms or a solid matrix and excipients for the tablet and capsule forms.

What is the Core Purpose of Hydal?

The core purpose of Hydal is to provide comprehensive and effective relief of moderate to severe discomfort by modulating neurological perception. It achieves this by binding to specialized mu-opioid receptors in the central nervous system, which effectively inhibits the transmission of pain signals. The primary pharmacological action of hydromorphone is its high affinity for the mu-opioid receptor. This mechanism allows the medication to dampen the pain message itself while also altering the emotional processing of the discomfort, serving the primary therapeutic benefit of establishing patient comfort in acute or chronic high-intensity pain scenarios.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Hydal?

Possible Side Effects and Safety Information

The safety characteristics of Hydromorphone (Hydal) are consistently documented in official regulatory documents, primarily involving effects on the nervous and gastrointestinal systems, and the serious risk of respiratory depression.

Official Adverse Reactions by Frequency

Adverse reactions are classified by frequency based on clinical study data, according to regulatory standards (e.g., EMA/FDA). The most frequently reported effects are generally categorized as Very Common or Common:

Classification Examples of Reactions (SOC Category)
Most Common Constipation, Nausea, Vomiting, Somnolence (Drowsiness), Headache, Dizziness (Nervous System & GI Disorders)
Common Pruritus (Itching), Sweating, Dry mouth, Euphoria (Skin & Psychiatric Disorders)

Documented Serious Adverse Reactions

The official labeling emphasizes the risk of severe adverse reactions. The most serious safety concern consistently documented is Life-Threatening Respiratory Depression, which can lead to respiratory arrest. Other serious events listed in regulatory texts include severe Circulatory Depression (hypotension, shock), Cardiac Arrest, and the risk of Adrenal Insufficiency.

Safety Considerations for Specific Populations

Regulatory information addresses specific safety patterns for certain groups. Older adults may exhibit increased sensitivity to CNS and respiratory depression. Patients with Renal or Hepatic Impairment may require specific considerations due to the potential for the drug to accumulate in the body.

Patterns Related to Exposure

Side effects, including dizziness and nausea, may be more pronounced at the initiation of treatment or following a dose increase, as documented in regulatory information. Physical Dependence and the development of Drug Tolerance are official safety characteristics associated with long-term exposure.

Overdose and Emergency Response

Hydromorphone overdose is classified in regulatory documents as a life-threatening medical emergency, with the chief documented hazard being severe respiratory depression.

Documented Overdose Manifestations

Official labeling describes a pattern of manifestations that includes slow and shallow breathing or apnea, profound Central Nervous System (CNS) depression progressing from somnolence to coma, pinpoint pupils (miosis), cold and clammy skin, skeletal muscle flaccidity, and hypotension (low blood pressure). Severe overdose may result in circulatory depression, shock, and potentially death.

When Immediate Medical Help is Required

Regulators mandate that individuals seek immediate medical help right away for any suspected overdose. Emergency services (such as 911) or a poison control center must be called immediately, and the official guidance states that one must not delay calling for help.

Supportive and Emergency Measures

Pure opioid antagonists, such as Naloxone, are the specific antidotes for reversing respiratory depression. Overdose management involves administering this antidote and providing symptomatic and supportive treatment, which may include breathing support (e.g., assisted ventilation) and close hospital monitoring of vital signs.

Population-Specific Notes

Accidental ingestion of even one dose can result in a fatal overdose, particularly in children. Additionally, elderly and debilitated patients are noted to be at increased risk for life-threatening respiratory depression.

Therapeutic Uses of Hydal

Quick Facts

  • Therapeutic Domain: Pain management
  • Primary Indication: Addresses severe pain
  • Use Context: Utilized when alternative therapeutic approaches are not adequate or are poorly tolerated

Hydal (Hydromorphone) is an agent prescribed for the management of severe pain. This medication is typically considered when the patient's condition requires a treatment that acts on the central nervous system to modify the perception of discomfort. Its use is appropriate for pain that is not sufficiently addressed by non-opioid options or other initial treatments.

The therapeutic approach with Hydal involves addressing both acute and chronic severe pain conditions where continuous management is necessary. The use of the extended-release formulation is specifically reserved for opioid-tolerant individuals who require around-the-clock, long-term treatment. A healthcare professional determines the appropriate use of this medication based on an assessment of the patient's condition and history.

Eligibility and Restrictions for Use

Hydal (Hydromorphone) is an opioid analgesic for use only in specific populations as defined by regulatory bodies. Eligibility is strictly limited by the presence of certain medical conditions and a patient's physiological status, especially for potent formulations.

Populations Who Must Not Use Hydal (Contraindications)

Use is absolutely prohibited for patients with:

  • Known Hypersensitivity to hydromorphone or any components of the formulation.
  • Significant Respiratory Depression or acute or severe Bronchial Asthma in an unmonitored setting.
  • Gastrointestinal Obstruction, including known or suspected Paralytic Ileus.
  • Opioid Non-Tolerant Status (a strict contraindication for extended-release and high-potency injectable forms).
  • Circulatory Shock (for high-potency injectable formulations).

Eligibility Based on Age and Organ Function

Population Group Regulatory Status Restriction Context
Pediatric Patients (<12) Use Not Established / Not Recommended Safety and effectiveness have not been established in this age group.
Older Adults (Geriatric) Use with Caution Initiate treatment at the low end of the dosing range due to increased sensitivity and potential for reduced organ function.
Renal or Hepatic Impairment Conditional Use Patients require close monitoring; use should be initiated with a lower dose to avoid accumulation.
Pregnancy Not Recommended Prolonged use can result in Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.
Lactation (Breastfeeding) Not Recommended Hydromorphone is detected in human milk; nursing should not be undertaken while the patient is receiving the drug.

What should I know about interactions with other medicines?

The official interaction profile for Hydal (Hydromorphone) is defined by its potential for additive pharmacodynamic effects and specific regulatory restrictions.

Contraindicated Combinations and Timing Rules

The co-administration of Hydal with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. A mandatory separation period requires that at least 14 days must elapse after discontinuing an MAOI before Hydal treatment can be initiated.

Pharmacodynamic and Substance Interactions

Co-administration with Central Nervous System (CNS) depressants (including benzodiazepines and other opioids) is documented to result in an additive pharmacologic effect, which increases the risk of profound sedation and respiratory depression. Regulatory documents require the limitation of dosage and duration when these combinations are necessary.

Furthermore, the use of alcohol is restricted due to its additive CNS depressant effect and its potential to cause rapid drug release (dose dumping) in extended-release formulations, which can lead to high concentrations. Combining Hydal with serotonergic drugs carries a formal risk of serotonin syndrome, and co-administration with anticholinergic drugs increases the risk of severe constipation and paralytic ileus. Use with mixed agonist/antagonist opioids is restricted due to potential reduction of analgesic effect or the precipitation of withdrawal.

Metabolic Interaction Status

Unlike many other opioids, Hydromorphone's primary metabolism occurs via glucuronidation. Consequently, clinically significant pharmacokinetic interactions involving CYP450 enzymes (e.g., CYP3A4, CYP2D6) are not formally documented in the regulatory prescribing information.

Mechanism of Action

Agonism of Central Opioid Receptors

Hydal acts as an agonist at mu-opioid receptors predominantly located throughout the central nervous system (CNS), including the brain and spinal cord. This engagement of receptor-mediated signaling initiates a cascade that modifies the perception and transmission of signals within pain-modulating pathways, resulting in modified physiological responses via reduced neuronal excitability.


Modulation of Neurotransmitter Release

The binding of Hydal is coupled to inhibitory G-proteins, which decreases the intracellular concentration of cyclic AMP (cAMP). This interaction reduces calcium ion influx into presynaptic nerve terminals and increases potassium ion conductance, leading to membrane hyperpolarization. This restriction of neurotransmitter release influences systemic physiological outcomes by limiting the presynaptic availability of excitatory neurotransmitters, including Substance P and glutamate.


Regulation of Brainstem Centers

Beyond its primary effects on pain transmission pathways, Hydal influences systems where specific CNS mediators dominate, engaging mechanisms that modulate activity in the brainstem. This action affects and modulates the central nervous centers that govern the cough reflex and respiratory rhythm.

Dosage and Administration Information

The use of Hydromorphone Hydrochloride is governed by specific administration protocols. The medication is available for oral administration via immediate-release tablets, oral solution, or extended-release tablets, as well as parenteral administration through intravenous (IV), subcutaneous (SC), or intramuscular (IM) injection.

Dosing frequency is dependent on the product type. Immediate-release forms are typically taken every two to six hours as needed. In contrast, the extended-release formulation is reserved for opioid-tolerant individuals and is administered strictly once daily for around-the-clock management. Initial oral dosing for opioid-naïve adults commonly begins in the 2 mg to 4 mg range, while parenteral starting doses are lower, ranging from 0.2 mg to 2 mg depending on the route.

Specific handling procedures are mandatory for proper use. The IV solution must be injected slowly over a period of at least two to three minutes. Furthermore, the extended-release tablet requires a crucial administration restriction: it must be swallowed whole and must not be crushed, chewed, broken, or dissolved, as manipulating the tablet disrupts the controlled release of the medicine. Dosage adjustments are required for specific populations. Patients with hepatic or renal impairment must start therapy with one-fourth to one-half the usual starting dose, and dosing for older adults is typically initiated at the low end of the dosing range. Upon discontinuation, all forms require the dose to be gradually tapered rather than stopped abruptly.

Recent Clinical Evidence

Research evidence / Overview of Studies for Hydal

This section provides a summary of the clinical research conducted on Hydal (Hydromorphone Hydrochloride), describing the types of studies that exist, the outcomes they measured, and the overall state of the evidence, without offering advice or clinical guidance.


Research Exploring Acute Severe Pain

Research for the immediate-release forms of Hydal is mainly derived from short-term, randomized controlled trials (RCTs). These studies were used in research exploring short-term symptom changes associated with high-intensity pain, such as post-operative discomfort. Researchers focused on outcomes related to physical discomfort, specifically measuring changes in pain intensity scores at early time points. Findings describe patterns observed in the studies related to a rapid onset of measured analgesic activity. Key limitations include modest sample sizes and heterogeneity in the types of pain studied.


Research Exploring Chronic Severe Pain

Evidence for the extended-release capsule form was evaluated in intermediate-term RCTs, sometimes including specialized randomized withdrawal designs for opioid-tolerant individuals. These studies examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. Studies monitored patients over defined time intervals, and findings indicate a relative stability in pain scores was observed during the study period among the patients using the extended-release formulation.


Research Exploring Comparative Outcomes and Gaps

Hydal was observed in studies comparing its analgesic performance to other strong opioid medications, such as Morphine. Findings describe patterns where Hydal was observed to show similar overall measured analgesic activity in studies that included these drugs as comparators. Research also focused on special populations, with findings describing similar changes in measured pain scores between Hydal and Morphine in older adult patients. However, comparative evidence is lacking in large-scale RCTs, and the full range of long-term effects are not fully established by sufficient controlled trials extending beyond one year for chronic pain.

Key Studies & References Hydromorphone Hydrochloride Oral Solution and Tablets Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Hydal (FAQ)


Q: How quickly can I expect Hydal to start working?

A: According to the official product information, the maximum pain-relieving effect for immediate-release oral forms of Hydal is typically reached between 30 and 60 minutes after the medicine is taken. This time frame describes when the drug concentration used for measurement typically reaches its highest point.

Q: How long do the effects of Hydal usually last?

A: Regulatory documents indicate that the duration of pain relief associated with immediate-release Hydal generally lasts for approximately 4 to 6 hours. This timeframe is one factor considered in defining typical administration schedules.

Q: Can taking Hydal lead to unusual tiredness or fatigue?

A: Official regulatory sources list somnolence, or drowsiness, as a common adverse reaction to Hydal. While 'fatigue' is not always listed as a separate reaction, somnolence is related to reduced alertness.

Q: What happens in the body when Hydal starts working?

A: Official descriptions state that the active substance in Hydal works by binding to specialized mu-opioid receptors, which are located throughout the central nervous system. This action modifies how the body perceives and transmits pain signals, leading to the pain-relieving effect.

Q: Is it normal to feel slightly dizzy when first starting Hydal?

A: Dizziness is officially listed as a very common adverse reaction. Official information also notes that side effects, including dizziness, may be more noticeable when treatment is first initiated.

Q: Is Hydal known to cause weight gain?

A: Weight change (gain or loss) is not typically listed as a common or frequently occurring adverse reaction in the official regulatory documentation for this medication.

Q: Does Hydal affect sleep patterns?

A: Regulatory documentation commonly lists somnolence (drowsiness) as a possible adverse effect. Less frequently, official sources may also list insomnia, which is the inability to sleep, as a possible adverse reaction.

Q: Is Hydal a type of pain reliever?

A: Yes, official government sources classify the active ingredient in Hydal as an opioid analgesic. Analgesics are a type of medicine used specifically for pain relief.

Q: Can Hydal be used alongside common over-the-counter cold medicines?

A: Official information describes a risk of additive effects, such as increased sedation and profound respiratory depression, when Hydal is used with certain central nervous system (CNS) depressants. Some over-the-counter cold medicines may contain ingredients that fall into this category.

Q: Are there any foods or drinks that should be avoided while using Hydal?

A: Regulatory documents restrict the consumption of alcohol while using Hydal due to an increased risk of serious adverse effects. However, no specific foods or non-alcoholic drinks are generally prohibited in the official prescribing information.

Q: Is it safe to take Hydal if I have high blood pressure?

A: Official regulatory labels include warnings regarding cardiovascular risks, specifically mentioning circulatory depression and shock as potential serious adverse events. Official labeling suggests caution may be necessary when the drug is used by patients with pre-existing cardiovascular conditions.

Q: Does the medicine Hydal come in different strengths?

A: Yes, regulatory product information confirms that Hydal is available in multiple dosage strengths to accommodate the different formulations, such as immediate-release tablets and injections.

Q: Is there a generic version of Hydal available?

A: Regulatory records from bodies like the FDA indicate that the active ingredient, hydromorphone hydrochloride, has approved generic equivalents that are available.

Q: Are there official research studies showing how well Hydal works?

A: Yes, official regulatory documents provide summaries of clinical research. These include randomized controlled trials (RCTs) that were conducted to measure and evaluate the analgesic (pain-relieving) effects of Hydal.

Q: What does the latest research say about Hydal's long-term use?

A: Official summaries of clinical evidence state that the full range of long-term effects for chronic use are not fully established by controlled trials extending beyond a duration of one year. This represents a known limitation in the existing clinical data.

Q: What are the official warnings or precautions listed for Hydal?

A: Official documents list numerous warnings and precautions, including the serious risks of respiratory depression, the potential for drug tolerance to develop, and the risk of physical dependence. Risks are also outlined for specific patient populations.

Q: How long after stopping Hydal does it typically stay in the body?

A: Official pharmacokinetic data defines the half-life of the active ingredient, which describes the rate at which the substance is naturally cleared from the body. This data is defined by pharmacokinetic information available in the product label.

Q: Can Hydal affect my ability to drive or operate machinery?

A: Official regulatory labels advise that Hydal may impair the mental and physical abilities required to perform potentially hazardous tasks. These tasks include driving a car or operating heavy machinery.

Q: What is the purpose of the boxed warning, if any, for Hydal?

A: The Boxed Warning is a formal requirement by the FDA to call attention to the most serious risks associated with the drug. This regulatory feature calls attention to the most serious risks associated with the drug, which include potential addiction, abuse, misuse, and severe respiratory depression.

Q: Is Hydal considered a specialized medication?

A: Regulatory classifications describe Hydal as a potent Schedule II controlled substance intended for the management of pain severe enough to require an opioid analgesic. This classification and intended use are associated with specialized pain management.

Q: Are there any known issues with taking Hydal while traveling?

A: Official documents classify Hydal as a controlled substance, which means it is subject to specific legal and transportation restrictions. The legal requirements associated with controlled substances may apply when traveling.

Q: What are the reasons someone would need to stop taking Hydal?

A: Reasons for discontinuing the medication are often related to the development of severe adverse reactions, such as unmanaged respiratory depression. Official information also notes that the medicine may be stopped if it is not providing the intended benefit or if the patient switches to another therapy.

Q: Does Hydal affect laboratory blood test results?

A: Regulatory documents may note potential effects on laboratory tests, such as its detection in drug screening panels. Regulatory documents may also note the potential for changes in certain markers, such as liver enzymes.

Q: Can I take other pain medications while using Hydal?

A: Regulatory information specifically warns against combining Hydal with other opioid analgesics and central nervous system (CNS) depressants due to the risk of dangerous additive effects.

Q: Is Hydal available without a prescription in other countries?

A: Across major international regulatory authorities, Hydal is consistently classified as a prescription-only medicine. This status is maintained due to its potent nature and its high potential for abuse and physical dependence.

Q: Does Hydal have potential interactions with certain vitamins?

A: Official drug interaction information specifies combinations with general CNS depressants and serotonergic agents. This suggests that caution is warranted regarding vitamins or supplements that share similar properties or effects.

Q: Does Hydal interact with herbal supplements?

A: Official drug interaction information specifies combinations with serotonergic drugs and CNS depressants. Official information suggests caution is warranted regarding herbal supplements that share similar properties or effects.

How should Hydal be stored and disposed of?

Storage Conditions and Requirements

Hydal (Hydromorphone Hydrochloride) must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F).

  • The medication must be kept in a tightly closed container and protected from moisture and excessive heat.
  • The liquid oral solution formulation must not be frozen.
  • Due to the risk of accidental poisoning, the medication must be stored securely, out of the reach and sight of children.

Official Disposal Instructions

Official regulatory guidance specifies strict disposal protocols for this controlled substance.

  • The preferred method for discarding unused or expired Hydal is through an authorized drug take-back program.
  • If a take-back program is unavailable, the FDA recommends immediately flushing the unused medicine down the toilet to prevent accidental ingestion, which can be fatal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydal found in:

A-Z Index: